Mobile

An Open-Label, Randomized Phase 2 Study of ABT-869 in Combination With mFOLFOX6 (Oxaliplatin, 5-Fluorouracil, and Folinic Acid) Versus Bevacizumab in Combination With mFOLFOX6 as Second-line Treatment...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-007081-38

An Open-Label, Randomized Phase 2 Study of ABT-869 in Combination With mFOLFOX6 (Oxaliplatin, 5-Fluorouracil, and Folinic Acid) Versus Bevacizumab in Combination With mFOLFOX6 as Second-line Treatment of Subjects With Advanced Colorectal Cancer

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess if the addition of oral ABT-869 to mFOLFOX6 (5-fluorouracil, folinic acid, and oxaliplatin) can prolong progression-free survival (PFS) compared to bevacizumab plus mFOLFOX6 as second-line treatment in subjects with advanced colorectal cancer.

Critère d'inclusion

  • Advanced colorectal cancer

Liens